Doxazosin Mesylate For Nocturia In Patients With BPH

Benign prostatic hyperplasia is one of the most common chronic andprogressive urinary system diseases for the elderly man. As one of lowerurinary tract symptoms in patients with BPH, nocturia is believed to be theearliest and most common symptom, which can seriously affect the patient’snormal sleep and make them suffer from the mental fatigue, decreased qualityof life. Someone who experience too much nocturia may appear neurastheniaand make the body resistance to decline. Also, some organic changes wouldhappen. Therefore, it’s time to pay great attention to nocturia and try toimprove the health level of patients being bothered by the bothersomedisease.Objective: To the observe the effect and application of DoxazosinMesylate when being uesd to treat benign prostatic hyperplasia patients withnocturia.Method:51cases of BPH patients experiencing nocturia confirmed byultrasonography were involved in this study. All patients completed the7dvoiding diary including nocturnal voids, urine volume, nocturnal polyuriaindex, the sleep time disturbed by the first voiding and the QOL scores. Theinvolved51patients were randomized to the treatment group(25cases) andmatched group(26cases).A oral drug treatment of doxazosin mesylate wasgiven to the treatment group with a regular dose—4mg.All patients wereadvised to convey fluid restrictions (avoidance of caffeinated beverages,alcohol, etc.).After4weeks’ treatment, the7d voiding diary was used torecord the situation of both group. In the course of treatment, the bloodpressure of patients in experimental group was carefully watched. And someadverse reactions such as dizziness and orthostatic hypotension was alsorecorded in the study. A comparison of nocturnal voids, urine volume,nocturnal polyuria index, first sleep period and the QOL scores were summarized by statistical software SPSS21.0. If P value was less than0.05,we thought the difference were statistical significance.Results: After4weeks’ drug therapy, In the doxazosin group, mostpatients reported a good response with reduced nocturnal voids3.3±0.8vs1.8±0.5).The mean duration of the first sleep period was improved by44min(120±21vs164±18). Compared with the control group, the doxazosin groupshowed significantly an improvement at the QOL scores. But the doxazosingroup didn’t give a decresed nocturia urine output and nocturnal polyuriaindex.In addition, No adverse actions occurred during the treatment All patientswith benign prostatic hyperplasia patients were successfully completed theexperiment.Conclusions: Short-term oral doxazosin is an effective and well toleratedtreatment for benign prostatic hyperplasia suffering from the bothersomenocturia.Doxazosin mesylate could improve the quality of life by reducing thefrequency of nocturnal voids in patients with benign prostatic hyperplasia. Butdoxazosin mesylate did not show a significant difference at reducing nocturiaurine output.